Rash and edema shortly after initial exposure to low dose cenobamate
Cenobamate (CNB) is an antiseizure medication (ASM) approved for the treatment of focal epilepsy. Rash and edema are uncommon adverse effects of this medication. We report two patients with medically refractory epilepsy (MRE) who received CNB and developed chest and facial rash and edema after the i...
Saved in:
| Main Authors: | Christopher Saouda, Yamane Makke, Helen Edelberg, Mohamad Z. Koubeissi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Epilepsy & Behavior Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589986425000607 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cenobamate reduces epileptiform activity in the ex vivo F98 rat glioma model
by: Ferdinand Forberger, et al.
Published: (2025-08-01) -
Increase of Brivaracetam serum concentration with introduction of Cenobamate
by: Lena Bender, et al.
Published: (2025-04-01) -
Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox–Gastaut Syndrome: A Retrospective Chart Review
by: Karen Keough, et al.
Published: (2025-06-01) -
A french real-world experience with cenobamate in patients with drug-resistant focal epilepsy: A retrospective observational study
by: Antoine Plaquevent, et al.
Published: (2025-09-01) -
Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
by: Patrick M. House, et al.
Published: (2025-06-01)